Showing 5951-5960 of 9076 results for "".
- AAD Pediatric Guidelines Give Strong Backing to Roflumilast Creamhttps://practicaldermatology.com/news/aad-pediatric-guidelines-give-strong-backing-to-roflumilast-cream/2486794/Arcutis Biotherapeutics announced that ZORYVE (roflumilast) cream has received a strong recommendation in the American Academy of Dermatology (AAD) clinical practice guidelines for pediatric atopic dermatitis (AD), marking inclusion in the organization’s first guid
- AQUA Announces Partnership with Steele Dermatologyhttps://practicaldermatology.com/news/aqua-announces-partnership-with-steele-dermatology/2486768/AQUA Dermatology has announced a new partnership with Steele Dermatology, expanding its presence in the Atlanta metropolitan area, according to a press release.AQUA, backed by private equity firms Gryphon Investors and GTCR, continues to scale its network
- Acquisition Broadens Newmedical’s Scar Care and Skincare Platformhttps://practicaldermatology.com/news/strategic-acquisition-broadens-newmedicals-scar-care-and-skincare-platform/2486628/Newmedical Technology, Inc. announced its acquisition of Derma Made®, marking a strategic expansion of its dermatology and aesthetics portfolio, according to a news release from the company. The transaction will meld Newmedica
- SEEN Launches Dermatologist-Designed Clarifying Shampoo as Scalp Care Trend Surgeshttps://practicaldermatology.com/news/seen-launches-dermatologist-designed-clarifying-shampoo-as-scalp-care-trend-surges/2486594/As scalp care continues to gain momentum within the broader beauty and wellness industry, dermatologist-founded brand SEEN is expanding its portfolio with the launch of its new Scalp Clarifying Shampoo, a product designed to bridge the gap between hair care and skin
- Analysis Shows Gaps in Access to Pediatric Dermatologyhttps://practicaldermatology.com/news/analysis-shows-gaps-in-access-to-pediatric-dermatology/2486593/Racially minoritized families face persistent and multifactorial barriers when accessing pediatric dermatology care, according to a qualitative study of 32 parents.The study researchers explored caregiver perspectives through semistructured interviews, fo
- Study Links Vitiligo to Higher Autoimmune and Infection Burden in US Cohorthttps://practicaldermatology.com/news/vitiligo-linked-to-higher-autoimmune-and-infection-burden-in-us-cohort/2486572/New data from a large retrospective study suggested patients with vitiligo experience higher rates of several comorbidities and safety events compared with matched controls. Investigators analyzed Optum Market Clarity EHR dat
- Paper: AI Gains Ground in Cosmetic Dermatology Workflowshttps://practicaldermatology.com/news/paper-ai-gains-ground-in-cosmetic-dermatology-workflows/2486551/A recent review in Dermatology and Therapy assessed the growing use of artificial intelligence (AI) across aesthetic dermatology, with the authors reporting increased adoption and highlighting its use in many aspects of prac
- Icotrokinra Shows Sustained Skin Clearance Through 52 Weeks in Psoriasishttps://practicaldermatology.com/news/icotrokinra-shows-sustained-skin-clearance-through-52-weeks-in-psoriasis/2486494/New 52-week data presented at the American Academy of Dermatology (AAD) 2026 Annual Meeting highlight the sustained efficacy and safety of icotro
- Phase 3 Data Highlight Early and Broad Response With Deuruxolitinibhttps://practicaldermatology.com/news/phase-3-data-highlight-early-and-broad-response-with-deuruxolitinib/2486483/Two posters presented at the American Academy of Dermatology (AAD) 2026 Annual Meeting provide complementary Phase 3 evidence supporting the efficacy of deuruxolitinib, an oral Janus kinase (JAK)1/JAK2 inhibitor, in adults with severe alopecia areata (AA). Both analyses pooled data from th
- Rademikibart Shows High Long-Term Efficacy in Atopic Dermatitishttps://practicaldermatology.com/news/rademikibart-shows-high-long-term-efficacy-in-atopic-dermatitis/2486495/Rademikibart, a next-generation anti–IL-4 receptor alpha monoclonal antibody, demonstrated robust and sustained efficacy in moderate-to-severe atopic dermatitis (AD) through 52 weeks, according to Phase 3 RADIANT-AD data presented by Cheng Zhou, MD, at the American Academy of Dermatology (AAD) 20